Biotech Companies

353 companies | Drug discovery and development companies

#	COMPANY	THERAPEUTIC AREAS	STAGE
1.	4D Pharma plc Leeds, United Kingdom	Oncology Immunology Gastroenterology	Preclinical to Phase II (at time of administration)	VIEW
2.	ADMA Biologics, Inc. Ramsey, New Jersey, United States		Commercial + Preclinical	VIEW
3.	AGS Therapeutics Paris, France	Ophthalmology Immunology Infectious Disease+2	Preclinical	VIEW
4.	ASKA Pharmaceutical Co., Ltd. Tokyo, Japan	Gastroenterology	Commercial	VIEW
5.	Aardvark Therapeutics San Diego, USA	Rare Diseases Metabolic	Phase 3	VIEW
6.	Abivax Paris, France	Immunology Gastroenterology	Phase 3	VIEW
7.	Acadia Pharmaceuticals Inc. San Diego, USA	Neuroscience Rare Diseases	Commercial	VIEW
8.	Acelot South San Francisco, California, USA	Metabolic Oncology	Preclinical	VIEW
9.	Acrux Melbourne, Australia	Dermatology Metabolic	Commercial	VIEW
10.	Aerogen Pharma San Mateo, USA / Galway, Ireland	Respiratory	Phase 3	VIEW
11.	Affitech Copenhagen, Denmark (with R&D in Oslo, Norway and San Francisco, USA)	Oncology Immunology Infectious Disease	Clinical	VIEW
12.	Agios Pharmaceuticals Cambridge, USA	Rare Diseases Hematology Metabolic	Commercial	VIEW
13.	Agomab Therapeutics Antwerp, Belgium	Gastroenterology Rare Diseases	Phase 2	VIEW
14.	Ajou University Suwon, South Korea	Oncology Immunology Neuroscience+2	Phase 3	VIEW
15.	Akebia Therapeutics Cambridge, USA	Rare Diseases	Commercial	VIEW
16.	Akribes Biomedical Vienna, Austria	Dermatology	Preclinical	VIEW
17.	Alkeus Pharmaceuticals Cambridge, USA	Ophthalmology Rare Diseases	Phase 3	VIEW
18.	Allergy Therapeutics Worthing, United Kingdom		Phase 3 and Phase 1/2	VIEW
19.	Allygen Biosciences Shanghai, China	Oncology Immunology	Preclinical	VIEW
20.	Anavex Life Sciences Corp. New York, United States	Oncology	Phase 2\|Phase 3	VIEW
21.	Aprogen Seongnam-si, South Korea	Oncology Immunology	Commercial	VIEW
22.	Aquinas Companies, LLC (Fannin Innovation Studio) Houston, Texas, USA	Oncology Infectious Disease Cardiovascular+2	Phase 2	VIEW
23.	Arcus Biosciences Hayward, United States	Oncology Immunology	Phase 3	VIEW
24.	Ardelyx Waltham, Massachusetts, USA	Gastroenterology	Commercial	VIEW
25.	Ark Biosciences Shanghai, China	Respiratory Infectious Disease Neuroscience	Commercial	VIEW
26.	Artica Therapeutics Leiden, Netherlands	Immunology	Preclinical	VIEW
27.	Artificial Axon Labs Cambridge, Massachusetts, USA	Neuroscience	Discovery	VIEW
28.	AskGene Camarillo, California, United States	Oncology Immunology Ophthalmology	Phase 3	VIEW
29.	Asklepion Pharmaceuticals, LLC Baltimore, Maryland, USA		Phase 3	VIEW
30.	Asklepios BioPharmaceutical Research Triangle Park, North Carolina, USA	Metabolic	Phase 1\|Phase 2\|Preclinical	VIEW
31.	Aspen Global Incorporated Grand Bay, Mauritius	Oncology Cardiovascular Metabolic+1	Commercial	VIEW
32.	AtaiBeckley (formerly ATAI Life Sciences) Berlin, Germany (original); U.S. redomiciliation completed December 30, 2025		Phase 2	VIEW
33.	Autobahn Therapeutics San Diego, USA	Neuroscience	Phase 2	VIEW
34.	Autolus Therapeutics London, United Kingdom	Oncology Immunology Rare Diseases	Commercial + Phase 1/2	VIEW
35.	Avenzo Therapeutics San Diego, USA	Oncology	Phase 2	VIEW
36.	Axalbion Lausanne, Switzerland	Respiratory Ophthalmology Neuroscience	Phase 2	VIEW
37.	Azurity Pharmaceuticals Woburn, USA	Cardiovascular Metabolic Gastroenterology+2	Commercial	VIEW
38.	B.Grimm Pharma Bangkok, Thailand	Cardiovascular Gastroenterology Infectious Disease+1	Commercial	VIEW
39.	BIKEN Foundation Suita, Japan	Infectious Disease	Commercial	VIEW
40.	BRIM Biotechnology, Inc. Taipei, Taiwan	Ophthalmology Rare Diseases	Phase 3	VIEW
41.	BeOne Medicines (formerly BeiGene) Cambridge, Massachusetts, United States (corporate); Basel, Switzerland (post-redomiciliation May 2025)	Oncology	Phase 1-3 and Commercial	VIEW
42.	Belief BioMed Shanghai, China	Rare Diseases Hematology Neuroscience+1	Commercial	VIEW
43.	BenevolentAI London, United Kingdom	Oncology Immunology Neuroscience+3	Phase 1\|Phase 2\|Preclinical	VIEW
44.	Berg Health Framingham, Massachusetts, USA	Oncology Neuroscience Rare Diseases	Phase 1/2	VIEW
45.	Bharat Biotech Hyderabad, India	Infectious Disease Oncology	Commercial	VIEW
46.	BioCardia, Inc. Sunnyvale, California, USA	Cardiovascular Respiratory	Phase 3	VIEW
47.	BioMed Valley Discoveries Kansas City, Missouri, USA	Oncology Immunology Rare Diseases+1	Clinical (Phase 1-2)	VIEW
48.	BioNTech SE Mainz, Germany	Oncology Infectious Disease Rare Diseases	Commercial	VIEW
49.	Biomea Fusion San Carlos, USA	Metabolic Oncology	Phase 2	VIEW
50.	Biotest AG Dreieich, Germany	Hematology	Phase 2\|Phase 3\|Commercial	VIEW
51.	Biotest AG Dreieich (Frankfurt), Germany	Hematology	Phase 3/Commercial	VIEW
52.	BlueRock Therapeutics Cambridge, USA	Neuroscience Cardiovascular Ophthalmology+1	Phase 3	VIEW
53.	Blueprint Medicines Cambridge, USA	Oncology Hematology Immunology+1	Commercial	VIEW
54.	Boostimmune Seoul, South Korea	Oncology Immunology	Preclinical	VIEW
55.	Bota Biosciences Hangzhou, China (International HQ in Lafayette, CA, USA)		Commercial	VIEW
56.	BridgeBio Oncology Therapeutics, Inc. South San Francisco, USA	Oncology	Phase 1	VIEW
57.	CDR-Life Schlieren, Zurich, Switzerland	Oncology Immunology Ophthalmology	Phase 1	VIEW
58.	CECOS University of Information Technology and Emerging Sciences Peshawar, Pakistan	Oncology Neuroscience Infectious Disease	Preclinical	VIEW
59.	CEPI Oslo, Norway	Infectious Disease	Commercial	VIEW
60.	CG Oncology, Inc. Irvine, USA	Oncology	Phase 3	VIEW
61.	CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne, Switzerland	Oncology Immunology Neuroscience+2	Phase 3	VIEW
62.	Caldera Therapeutics Cambridge, USA	Immunology Gastroenterology	Phase 1	VIEW
63.	Calico Life Sciences South San Francisco, United States	Oncology Neuroscience Immunology	Phase 2	VIEW
64.	Calidi Biotherapeutics San Diego, USA	Oncology	Phase 2	VIEW
65.	Cantargia AB Lund, Sweden	Oncology Immunology	Phase 1 - Phase 2	VIEW
66.	Cardurion Pharmaceuticals Burlington, United States	Cardiovascular	Phase 2	VIEW
67.	Carrick Therapeutics Dublin, Ireland	Oncology	Phase 2	VIEW
68.	Cell-Tx Seoul, South Korea	Neuroscience Oncology Ophthalmology	Preclinical	VIEW
69.	Celon Pharma Łomianki, Poland	Neuroscience Oncology Immunology+1	Phase 3	VIEW
70.	Celularity Inc Florham Park, New Jersey, USA	Oncology	Phase 1/2 and Phase 2	VIEW
71.	Center for Neuromusculoskeletal Restorative Medicine Limited Shatin, Hong Kong	Neuroscience Rare Diseases	Preclinical	VIEW
72.	Center of Molecular Immunology (CIM) Havana, Cuba	Oncology Immunology	Commercial	VIEW
73.	Centrexion Therapeutics Boston, Massachusetts, United States	Immunology	Phase 1-3	VIEW
74.	Cerevel Therapeutics Cambridge, Massachusetts, USA		Phase 1-3	VIEW
75.	Chengdu Kanghong Pharmaceutical Group Chengdu, China	Ophthalmology Neuroscience Oncology	Commercial	VIEW
76.	Chiba University Chiba, Japan	Oncology Immunology Rare Diseases+3	Phase 2	VIEW
77.	China Medical System Holdings Ltd. Shenzhen, China	Dermatology Gastroenterology Ophthalmology+1	Commercial	VIEW
78.	China Medical University Hospital (CMUH) Taichung, Taiwan	Oncology Neuroscience Cardiovascular+2	Phase 2	VIEW
79.	Chongqing PegBio Biotechnology Co., Ltd. Chongqing, China	Gastroenterology Hematology Oncology	Phase 3	VIEW
80.	Choose Life Biotech SA Bellinzona, Switzerland	Immunology Infectious Disease Oncology	Preclinical	VIEW
81.	Chung-Ang University Seoul, South Korea	Oncology Cardiovascular Immunology+2	Phase 3	VIEW
82.	Cincinnati Children's Hospital Medical Center Cincinnati, USA	Oncology Immunology Rare Diseases+4	Commercial	VIEW
83.	Circio Holding ASA Lysaker, Norway	Oncology Immunology Gene Therapy	Phase 1/2	VIEW
84.	City of Hope Duarte, California, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
85.	Clasp Therapeutics Rockville, Maryland, USA	Oncology	Phase 1	VIEW
86.	Codexis, Inc. Redwood City, California, USA	Rare Diseases Metabolic	Commercial	VIEW
87.	Constructor Group Schaffhausen, Switzerland	Oncology Infectious Disease Neuroscience	Preclinical	VIEW
88.	Corline Biomedical AB Uppsala, Sweden	Metabolic Cardiovascular Neuroscience	Phase 2	VIEW
89.	Cosmo Pharmaceuticals N.V. Dublin, Ireland	Gastroenterology Dermatology Infectious Disease	Commercial	VIEW
90.	Crixmor LLC Malvern, Pennsylvania, USA	Immunology Gastroenterology Oncology	Discovery	VIEW
91.	Cugene Inc. Waltham, USA	Oncology Immunology	Phase 1	VIEW
92.	Cullinan Therapeutics Cambridge, USA	Oncology Immunology	Phase 3	VIEW
93.	CuraTeQ Biologics Hyderabad, India	Oncology Immunology Metabolic	Commercial	VIEW
94.	CuraVac Rixensart, Belgium	Immunology	Phase 1B (completed) \| Phase 2 (in preparation)	VIEW
95.	Curadev Pharma Pvt Ltd Noida, India	Oncology Immunology Metabolic	Phase 1	VIEW
96.	Curasight Copenhagen, Denmark	Oncology	Phase 1-2 Clinical	VIEW
97.	Curatis Liestal, Switzerland	Oncology Neuroscience Respiratory+1	Phase 3	VIEW
98.	Curative Biotechnology Inc Boca Raton, Florida, USA	Infectious Disease	Pre-Clinical\|IND-Enabling Studies	VIEW
99.	CureVac Tübingen, Germany	Oncology Infectious Disease Rare Diseases	Phase 2	VIEW
100.	CytoAgents Pittsburgh, USA	Oncology Immunology Infectious Disease+1	Phase 2	VIEW
101.	CytoDyn Inc Vancouver, Washington	Oncology Immunology	Phase 2 clinical	VIEW
102.	CytoImmune Therapeutics Duarte, USA	Oncology Hematology Immunology	Phase 1	VIEW
103.	CytoSen Therapeutics Orlando (Winter Springs), Florida, USA	Oncology Cell Therapy Immunology	Phase 2	VIEW
104.	CytoTools AG Heidelberg, Germany	Dermatology Cardiovascular Oncology	Phase 3	VIEW
105.	CytoVac Hørsholm, Denmark	Oncology	Phase 2	VIEW
106.	Cytochroma Edinburgh, United Kingdom	Cardiovascular Rare Diseases	Discovery	VIEW
107.	Cytocom, Inc. Fort Collins, Colorado, USA	Oncology Infectious Disease Hematology+1	Phase 2/Phase 3	VIEW
108.	CytomX Therapeutics, Inc. South San Francisco, California, United States	Oncology	Phase 1 (clinical), Preclinical (discovery collaborations)	VIEW
109.	Cytonics Corporation Jupiter, Florida, USA	Immunology	Phase 2	VIEW
110.	Cytonus Therapeutics Carlsbad, California, United States	Oncology Immunology Infectious Disease+1	Phase 1	VIEW
111.	Cytorex Biosciences Weston, Florida, USA	Oncology Metabolic Infectious Disease	Preclinical	VIEW
112.	Cytovation Bergen, Norway	Oncology Rare Diseases	Phase I/II - Phase II	VIEW
113.	Cytovia Therapeutics Aventura, Florida, USA	Oncology Immunology	Phase 1/2	VIEW
114.	Cyxone Malmö, Sweden	Immunology Neuroscience	Phase 2	VIEW
115.	D&D Pharmatech Seongnam-si, South Korea		Phase 2	VIEW
116.	DBV Technologies Châtillon, France	Immunology	Phase 3	VIEW
117.	Dankook University Yongin and Cheonan, South Korea	Oncology Neuroscience Rare Diseases+1	Phase 2	VIEW
118.	Dartmouth College Hanover, USA	Oncology Immunology Neuroscience+2	Phase 3	VIEW
119.	Day One Biopharmaceuticals Brisbane, United States	Oncology Rare Diseases	Commercial	VIEW
120.	Dendreon Pharmaceuticals Seal Beach, USA	Oncology	Commercial	VIEW
121.	Development Center for Biotechnology (DCB) Taipei, Taiwan	Oncology Immunology Infectious Disease	Preclinical	VIEW
122.	Dexcel Pharma Or Akiva, Israel	Oncology Cardiovascular Neuroscience+2	Commercial	VIEW
123.	DifGen Pharmaceuticals Miramar, USA	Ophthalmology Neuroscience	Commercial	VIEW
124.	Differential Bio Munich, Germany		Commercial	VIEW
125.	Dolor Therapeutics, Inc. Chicago, USA	Immunology	Preclinical	VIEW
126.	Drugs for Neglected Diseases initiative (DNDi) Geneva, Switzerland	Infectious Disease	Commercial	VIEW
127.	Duality Biologics Shanghai, China	Oncology Immunology	Phase 3	VIEW
128.	Duopharma Biotech Berhad Kuala Lumpur, Malaysia	Oncology Cardiovascular Metabolic+1	Commercial	VIEW
129.	E-Flask Seongnam, South Korea	Neuroscience Oncology	Phase 1	VIEW
130.	EEE Pharma Maharashtra, India	Infectious Disease Immunology Cardiovascular+1	Commercial	VIEW
131.	ETH Zürich Zurich, Switzerland	Oncology Immunology Neuroscience+4	Discovery	VIEW
132.	EUBREAST Esslingen, Germany	Oncology	Phase 3	VIEW
133.	Edge Therapeutics, Inc. Princeton, New Jersey, USA	Oncology Infectious Disease	Phase 3	VIEW
134.	Eledon Pharmaceuticals Irvine, USA	Immunology	Phase 2	VIEW
135.	Eleven Therapeutics Cambridge, United Kingdom	Infectious Disease	Discovery	VIEW
136.	Ellipses Pharma London, United Kingdom	Oncology	Phase 1/2	VIEW
137.	Emergent BioSolutions Gaithersburg, Maryland, USA	Infectious Disease	Commercial	VIEW
138.	Eneapharm Labège, France	Gastroenterology Rare Diseases	Clinical	VIEW
139.	Enlivex Therapeutics Ltd. Ness Ziona, Israel	Immunology Oncology Infectious Disease	Phase 2	VIEW
140.	Entact Bio Watertown, USA	Oncology Immunology Rare Diseases	Preclinical	VIEW
141.	EurimPharm Arzneimittel GmbH Saaldorf-Surheim, Germany	Oncology Immunology Neuroscience+2	Commercial	VIEW
142.	Everest Medicines Shanghai, China	Immunology Oncology Cardiovascular+1	Commercial	VIEW
143.	Evopoint Biosciences Suzhou, China	Oncology Infectious Disease Immunology	Commercial (NDA Stage)	VIEW
144.	Evotec SE Hamburg, Germany	Oncology Neuroscience Infectious Disease+1	Commercial	VIEW
145.	Exelixis Alameda, USA	Oncology	Commercial	VIEW
146.	Exeltis Florham Park, USA (Global HQ in Madrid, Spain)	Neuroscience Respiratory Dermatology+2	Commercial	VIEW
147.	FNCT Biotech Seongnam-si, South Korea	Oncology Immunology	Preclinical	VIEW
148.	Fishfa Biogenics Rajkot, India	Immunology Infectious Disease Oncology+1	Commercial	VIEW
149.	Flare Therapeutics Cambridge, MA, USA	Oncology	Phase 1-1B	VIEW
150.	Focus Care Pharmaceuticals B.V. Zaandam, Netherlands	Respiratory Neuroscience Cardiovascular+1	Commercial	VIEW
151.	Forma Therapeutics Inc Watertown, USA	Hematology Oncology Rare Diseases	Phase 3	VIEW
152.	Formation Bio New York, USA	Immunology Dermatology Neuroscience	Phase 3	VIEW
153.	Formycon AG Planegg-Martinsried, Germany	Ophthalmology Immunology	Commercial	VIEW
154.	Frontier Medicines South San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
155.	Fusion Pharmaceuticals Inc. Hamilton, Ontario, Canada	Oncology	Phase 1\|Phase 2\|Phase 3	VIEW
156.	G. H. Raisoni University Saikheda, India	Oncology Metabolic Neuroscience+1	Discovery	VIEW
157.	Galpha Laboratories Limited Mumbai, India	Infectious Disease Gastroenterology Dermatology	Commercial	VIEW
158.	Gan & Lee Pharmaceuticals Beijing, China	Metabolic Oncology Cardiovascular	Commercial	VIEW
159.	GenAns Biotech Beijing, China	Neuroscience Ophthalmology Oncology	Preclinical	VIEW
160.	Gene Oasis Singapore, Singapore	Oncology Neuroscience Immunology+1	Clinical	VIEW
161.	GeneBiology, Inc. Research Triangle Park, North Carolina, USA	Oncology Neuroscience Gastroenterology	Clinical	VIEW
162.	Genentech South San Francisco, California, United States	Oncology Immunology Rare Diseases+3	Discovery through Commercial	VIEW
163.	George Mason University Fairfax, USA	Oncology Infectious Disease Metabolic+2	Phase 2	VIEW
164.	Georgia Southern University Statesboro, USA	Oncology Infectious Disease Neuroscience+1	Discovery	VIEW
165.	Gesynta Pharma AB Stockholm, Sweden		Phase 2	VIEW
166.	Ghosts Past		-	VIEW
167.	Google (Google DeepMind / Isomorphic Labs) London, United Kingdom	Oncology Immunology Cardiovascular	Preclinical	VIEW
168.	Guangzhou Cellprotek Pharmaceutical Guangzhou, China	Neuroscience Cardiovascular Immunology+1	Phase 3 (Planning)	VIEW
169.	HBM Partners Zug, Switzerland	Oncology Immunology Neuroscience+3	Commercial	VIEW
170.	HCW Biologics Inc. Miramar, Florida, USA	Oncology Immunology	Phase 2	VIEW
171.	HERVolution Therapeutics Copenhagen, Denmark	Oncology	Preclinical	VIEW
172.	HGFH (Placeholder Entity) N/A		Discovery	VIEW
173.	Halozyme Therapeutics San Diego, USA	Oncology Immunology Neuroscience+3	Commercial	VIEW
174.	Hamad Bin Khalifa University (HBKU) Doha, Qatar	Oncology Metabolic Infectious Disease+1	Preclinical	VIEW
175.	Hansa Biopharma Lund, Sweden	Immunology Gene Therapy Oncology	Commercial	VIEW
176.	Hanyang University Seoul, South Korea	Oncology Neuroscience Infectious Disease+1	Phase 2	VIEW
177.	Harbour BioMed Shanghai, China	Oncology Immunology Ophthalmology	Phase 3	VIEW
178.	Healios K.K. Tokyo, Japan	Neuroscience Oncology Ophthalmology	Phase 3	VIEW
179.	Healis Therapeutics Cambridge, USA	Neuroscience	Phase 2/3	VIEW
180.	Heligenics Phoenix, Arizona, USA	Oncology Rare Diseases	Discovery	VIEW
181.	Hemerion Therapeutics Villeneuve d'Ascq, France	Oncology	Phase 1/2	VIEW
182.	Heranova Lifesciences Burlington, MA, USA		Clinical	VIEW
183.	Hevolution Foundation Riyadh, Saudi Arabia	Oncology Neuroscience Rare Diseases	Discovery	VIEW
184.	Holostem S.r.l. Modena, Italy	Ophthalmology Dermatology Rare Diseases	Commercial	VIEW
185.	Hone Bio Bristol, United Kingdom	Oncology Cardiovascular	Preclinical	VIEW
186.	Hong Kong University of Science and Technology (Guangzhou) Guangzhou, China	Oncology Neuroscience Ophthalmology+1	Phase 2	VIEW
187.	Howard University Washington, D.C., USA	Oncology Immunology Cardiovascular	Discovery	VIEW
188.	Hudson Pharmaceuticals Ltd. Dhaka, Bangladesh	Respiratory Ophthalmology Gastroenterology+2	Commercial	VIEW
189.	Huons Co., Ltd. Seongnam, South Korea	Ophthalmology Metabolic	Commercial	VIEW
190.	Hyloris Pharmaceuticals SA Liège, Belgium	Cardiovascular Infectious Disease Oncology+1	Commercial	VIEW
191.	IMTR Inc. Tokyo, Japan	Immunology Hematology Gastroenterology	Phase 1/2	VIEW
192.	ITESO, Universidad Jesuita de Guadalajara Tlaquepaque, Mexico		Discovery	VIEW
193.	Iasis Pharma Kamatero, Greece	Cardiovascular Dermatology Gastroenterology+3	Commercial	VIEW
194.	Idorsia Allschwil, Switzerland	Neuroscience Cardiovascular Immunology+1	Commercial	VIEW
195.	Immorna Biotherapeutics Morrisville, USA	Oncology Infectious Disease Dermatology+1	Phase 2	VIEW
196.	Immuneel Therapeutics Bengaluru, India	Oncology Hematology Immunology	Commercial	VIEW
197.	Immunis, Inc. Irvine, California, USA	Immunology	Phase 1/2	VIEW
198.	Immunomic Therapeutics, Inc. Rockville, Maryland, United States	Oncology Infectious Disease	Phase 1 - Phase 2	VIEW
199.	Incyte Wilmington, Delaware, USA	Oncology Hematology Dermatology+1	Commercial	VIEW
200.	Indian Immunologicals Limited Hyderabad, India	Infectious Disease Immunology	Commercial	VIEW
201.	Infinitopes Oxford, United Kingdom	Oncology	Phase 1/IIa	VIEW
202.	Initial Therapeutics South San Francisco, USA	Oncology Rare Diseases	Discovery	VIEW
203.	Innovacell Tokyo, Japan	Gastroenterology	Phase 3	VIEW
204.	Inresa Arzneimittel GmbH Freiburg im Breisgau, Germany	Oncology Infectious Disease	Commercial	VIEW
205.	Institute for Bioengineering of Catalonia (IBEC) Barcelona, Spain	Oncology Neuroscience Rare Diseases+2	Preclinical	VIEW
206.	Intellia Therapeutics Cambridge, USA	Rare Diseases Cardiovascular Neuroscience+2	Phase 3	VIEW
207.	Intelligene Taipei, Taiwan	Infectious Disease	Phase 1	VIEW
208.	International Centre of Insect Physiology and Ecology (ICIPE) Nairobi, Kenya	Infectious Disease	Discovery\|Preclinical\|Phase 2	VIEW
209.	International Livestock Research Institute (ILRI) Nairobi, Kenya	Infectious Disease	Commercial	VIEW
210.	Inventiva Pharma Daix, France	Oncology	Phase 3	VIEW
211.	Ionis Pharmaceuticals, Inc. Carlsbad, California, United States	Neuroscience Cardiovascular Immunology+1	Phase 1 through Commercial	VIEW
212.	Ironwood Pharmaceuticals Boston, USA	Gastroenterology Rare Diseases	Commercial	VIEW
213.	Janux Therapeutics San Diego, California, USA	Oncology Immunology	Phase 1	VIEW
214.	Jiayue Pharmaceutical Guangzhou, China	Oncology Immunology Infectious Disease	Phase 3	VIEW
215.	Jumpcan Pharmaceutical Taixing, Jiangsu, China	Gastroenterology Respiratory Oncology+1	Commercial	VIEW
216.	Junshi Biosciences Shanghai, China	Oncology Immunology Metabolic+1	Commercial	VIEW
217.	KM Biologics Co., Ltd. Kumamoto, Japan	Infectious Disease Hematology Immunology	Commercial	VIEW
218.	Kenai Therapeutics San Diego, USA	Neuroscience	Phase 1	VIEW
219.	Khartis Therapeutics, Inc. San Diego, USA	Immunology	Discovery	VIEW
220.	Kiniksa Pharmaceuticals London, United Kingdom	Cardiovascular Immunology Rare Diseases	Commercial	VIEW
221.	Knight Therapeutics Inc. Montreal, Canada	Oncology Hematology Infectious Disease+2	Commercial	VIEW
222.	Kura Oncology Inc San Diego, California, USA	Oncology	Phase 1\|Phase 2\|Phase 3\|Approved	VIEW
223.	Kyung Hee University Seoul, South Korea	Oncology Neuroscience Immunology+1	Phase 3	VIEW
224.	LFB USA Framingham, USA	Immunology	Commercial	VIEW
225.	LG Business Research Seoul, South Korea	Oncology Immunology Vaccines	Commercial	VIEW
226.	Laboratorios Bagó Buenos Aires, Argentina	Oncology Hematology Cardiovascular+3	Commercial	VIEW
227.	Laboratorios Viñas Barcelona, Spain	Dermatology	Commercial	VIEW
228.	Laurent Pharmaceuticals Montreal, Quebec, Canada		Phase 2/3	VIEW
229.	Libio Technology Suzhou, China	Cardiovascular Metabolic	Phase 1	VIEW
230.	Lotus Pharmaceutical Co., Ltd. Taipei, Taiwan	Oncology Neuroscience Cardiovascular	Commercial	VIEW
231.	Medac GmbH Wedel, Germany	Oncology Hematology Immunology	Commercial/Phase 3	VIEW
232.	MedinCell Montpellier, France		Commercial\|Phase 3\|Preclinical	VIEW
233.	Medison Pharma Petah Tikva, Israel	Oncology Rare Diseases Immunology+2	Commercial	VIEW
234.	Menarini Stemline New York, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
235.	Mersana Therapeutics Cambridge, USA	Oncology Rare Diseases	Phase 1	VIEW
236.	Merus N.V. Utrecht, Netherlands	Oncology	Commercial (BLA Stage)	VIEW
237.	Mesa Green Pharma Frederick, USA	Neuroscience	Preclinical	VIEW
238.	Metagenomi Emeryville, USA	Hematology Cardiovascular Rare Diseases+1	Preclinical	VIEW
239.	Micro CRISPR Vapi, India	Oncology Hematology Metabolic+1	Preclinical	VIEW
240.	Miltenyi Biotec Bergisch Gladbach, Germany	Oncology Immunology Hematology	Commercial	VIEW
241.	Mirum Pharmaceuticals Foster City, USA	Rare Diseases	Commercial	VIEW
242.	Moderna Cambridge, USA	Infectious Disease Oncology Rare Diseases+2	Commercial	VIEW
243.	Mogam Institute for Biomedical Research Seoul, South Korea	Rare Diseases Infectious Disease Oncology+1	Discovery\|Preclinical	VIEW
244.	N4 Pharma Chellaston, Derbyshire, United Kingdom	Oncology	Preclinical	VIEW
245.	NBE Therapeutics Basel, Switzerland	Oncology	Phase 1/2	VIEW
246.	NEOM Tabuk, Saudi Arabia		Commercial	VIEW
247.	NMDP Minneapolis, USA	Hematology Oncology Rare Diseases+1	Commercial	VIEW
248.	Nalu Bio San Francisco, USA		Preclinical	VIEW
249.	Nanocan Therapeutics Corporation Princeton, New Jersey (also noted as National Harbor, MD)	Oncology	Phase I/II	VIEW
250.	Nanophoria Milan, Italy	Cardiovascular Rare Diseases	Preclinical	VIEW
251.	Nanoscope Therapeutics Dallas, USA	Ophthalmology	Commercial	VIEW
252.	Naoclis Nantes, France	Oncology	Preclinical	VIEW
253.	Natural Remedies Bangalore, India	Dermatology	Commercial	VIEW
254.	Nerviano Medical Sciences Nerviano, Italy	Oncology Hematology	Phase 2	VIEW
255.	Neurocrine Biosciences San Diego, USA	Neuroscience Metabolic Rare Diseases	Commercial	VIEW
256.	Neurogene Inc. New York, NY	Neuroscience Rare Diseases	Phase 2	VIEW
257.	NextCure, Inc. Beltsville, Maryland, USA	Oncology Immunology	Phase 2	VIEW
258.	Nexus Bio Sydney, Australia	Oncology Immunology Cell Therapy+1	Commercial	VIEW
259.	Notogen Inc. Toronto, Canada		Preclinical	VIEW
260.	NovaDigm Consulting Group Rockville, Maryland, USA	Infectious Disease Dermatology	Phase 2	VIEW
261.	Noveome Biotherapeutics Pittsburgh, Pennsylvania, USA	Ophthalmology Neuroscience Dermatology	Phase 1-2	VIEW
262.	Novonesis Lyngby, Denmark		Commercial	VIEW
263.	Nutshell Therapeutics Shanghai, China (Pudong District, Building E, No. 1976 Middle Gaoke Road)	Oncology	Preclinical to Phase 1	VIEW
264.	Nuvation Bio New York, United States	Oncology	Commercial	VIEW
265.	OSIVAX Lyon, France		Phase 2	VIEW
266.	Oban BioPharma Stamford, USA	Neuroscience	Preclinical	VIEW
267.	Ocular Therapeutix, Inc. Bedford, Massachusetts, USA	Ophthalmology	Commercial	VIEW
268.	Okklo Life Sciences Nijmegen, Netherlands	Hematology Immunology Oncology	Phase 1	VIEW
269.	On/Off Therapeutics Paris, France	Oncology Immunology Rare Diseases	Preclinical	VIEW
270.	OncoWise Bio Sydney, Australia	Oncology	Discovery	VIEW
271.	Oncotelic Therapeutics Agoura Hills, California, USA	Oncology Rare Diseases	Phase 1\|Phase 2\|Phase 3	VIEW
272.	Optieum Biotechnologies Toon, Japan	Oncology	Preclinical	VIEW
273.	Orchard Therapeutics London, United Kingdom	Immunology Rare Diseases	Commercial	VIEW
274.	Panion & BF Biotech Inc. Taipei, Taiwan	Dermatology Infectious Disease Gastroenterology	Commercial	VIEW
275.	Partex NV Eschborn, Germany	Oncology Neuroscience Rare Diseases+1	Phase 2	VIEW
276.	Parvus Therapeutics South San Francisco, USA	Immunology Gastroenterology Metabolic	Phase 1/2	VIEW
277.	Phanes Therapeutics San Diego, California, USA	Oncology	Phase 1/2	VIEW
278.	Phanes Therapeutics, Inc. San Diego, California, USA	Oncology	Phase 1/2	VIEW
279.	PharmaResearch Co., Ltd. Seongnam-si, South Korea	Ophthalmology	Commercial	VIEW
280.	Pharmaforce (Pty) Ltd Midrand, South Africa		Commercial	VIEW
281.	Pherecydes Pharma SA Romainville, France	Infectious Disease	Phase 2	VIEW
282.	Phibro Animal Health Corporation Teaneck, New Jersey, USA		Commercial	VIEW
283.	Platinum Life Excellence Biotech Beijing, China	Immunology Hematology	Commercial	VIEW
284.	Prana Biosciences Worcester, USA	Oncology Immunology	Preclinical	VIEW
285.	Precigen Germantown, Maryland, USA	Oncology Infectious Disease Rare Diseases	Commercial	VIEW
286.	Quell Therapeutics London, United Kingdom	Immunology	Phase 2	VIEW
287.	QureBio Shanghai, China	Oncology Immunology	Phase 2	VIEW
288.	RNALead Toulouse, France	Oncology Immunology Infectious Disease	Phase 1	VIEW
289.	Rasan Pharmaceutical Industries Sulaymaniyah, Iraq	Infectious Disease	Commercial	VIEW
290.	Ratio Therapeutics Boston, USA	Oncology	Phase 1	VIEW
291.	Revolution Medicines Redwood City, USA	Oncology	Phase 3	VIEW
292.	Ribon Therapeutics Cambridge, MA, United States	Oncology Dermatology Respiratory	Phase 1/2	VIEW
293.	Ridgeline Discovery Basel, Switzerland	Oncology Immunology Metabolic+2	Discovery\|Preclinical\|Phase 1\|Phase 2	VIEW
294.	Rondo Therapeutics Hayward, USA	Oncology Immunology	Phase 1	VIEW
295.	SIFI Aci Sant'Antonio (Catania), Italy	Ophthalmology	Commercial	VIEW
296.	SNIPR Biome Copenhagen, Denmark	Infectious Disease Metabolic	Phase 1b-2a	VIEW
297.	Sama Pharmaceutical Seoul, South Korea	Respiratory Dermatology Gastroenterology	Commercial	VIEW
298.	Santa Ana Bio Alameda, USA	Immunology Dermatology	Preclinical	VIEW
299.	Saol Therapeutics Roswell, USA	Neuroscience Rare Diseases	Phase 3	VIEW
300.	Sarepta Therapeutics Cambridge, USA	Neuroscience Cardiovascular Rare Diseases	Commercial	VIEW
301.	Scenic Biotech Amsterdam, The Netherlands	Oncology Immunology Rare Diseases+1	Preclinical to IND-enabling	VIEW
302.	Sebela Pharmaceuticals Roswell, USA	Gastroenterology Dermatology	Commercial	VIEW
303.	Secura Bio Las Vegas, USA	Oncology Hematology	Commercial	VIEW
304.	Senti Biosciences South San Francisco, California, USA	Oncology Immunology	Phase 1	VIEW
305.	Sentien Biotech Lexington, Massachusetts, United States		Phase 1/2	VIEW
306.	Sentinel Oncology Cambridge, United Kingdom	Oncology	Preclinical to Phase 1	VIEW
307.	Shanghai Jeyou Pharmaceutical Co., Ltd. Shanghai, China (Pudong district)	Oncology Respiratory Immunology	Preclinical to Phase 2	VIEW
308.	SinSa Labs Lidingö, Sweden	Infectious Disease Ophthalmology Dermatology	Preclinical	VIEW
309.	Sinotherapeutics Inc. Shanghai, China	Oncology Neuroscience Gastroenterology	Commercial	VIEW
310.	Soleno Therapeutics, Inc. Redwood City, California, USA	Metabolic	Commercial	VIEW
311.	Southern Taiwan University of Science and Technology (STUST) Tainan City, Taiwan	Oncology	Preclinical	VIEW
312.	Spur Therapeutics London, United Kingdom		Phase 1/2 to Phase 3	VIEW
313.	StemGen Milan, Italy	Oncology	Phase 1/Phase 2	VIEW
314.	StemSynergy Therapeutics Miami, Florida, USA	Oncology Rare Diseases	Preclinical and IND-enabling	VIEW
315.	Stemline Therapeutics, Inc. New York, United States	Oncology	Commercial + Clinical Development	VIEW
316.	Stoke Therapeutics Bedford, USA (Moving to Waltham, MA in late 2026)	Neuroscience Ophthalmology Rare Diseases	Phase 3	VIEW
317.	Symmetra Bio Doha, Qatar	Cardiovascular	Discovery	VIEW
318.	TAE Life Sciences Irvine, California, United States	Oncology	Investigator Initiated Trials (IIT) - Early clinical stage	VIEW
319.	TRB Pharma Campinas, Brazil	Ophthalmology Neuroscience Dermatology	Commercial	VIEW
320.	TRG Ventures Hellerup, Denmark	Dermatology Immunology Neuroscience	Phase 3	VIEW
321.	TRIM-edicine, Inc. Columbus, Ohio, USA	Cardiovascular Dermatology	Preclinical	VIEW
322.	TS-VV GmbH Baesweiler, Germany		N/A	VIEW
323.	TVAX Biomedical, Inc. Lenexa, Kansas, United States	Oncology	Phase 2b/3	VIEW
324.	TYG Oncology Mansfield, Nottinghamshire, United Kingdom	Oncology Immunology	Phase 1	VIEW
325.	Tagworks Pharmaceuticals Nijmegen, Netherlands	Oncology	Phase 1	VIEW
326.	Tamkang University New Taipei City, Taiwan	Oncology Neuroscience Infectious Disease	Discovery	VIEW
327.	TechnoPhage Lisbon, Portugal	Infectious Disease Ophthalmology	Phase 1/IIa through Phase 3 in development	VIEW
328.	Terran Biosciences Miami Beach, Florida, USA		Phase 1\|Phase 2\|Phase 3\|Commercial (NM-101 FDA cleared)	VIEW
329.	The United Laboratories Hong Kong, China	Metabolic Ophthalmology	Commercial	VIEW
330.	Théa Open Innovation Clermont-Ferrand, France	Ophthalmology	Phase 1\|Phase 2\|Phase 3	VIEW
331.	Tongji University Shanghai, China	Oncology Cardiovascular Neuroscience	Phase 3	VIEW
332.	Tvardi Therapeutics Inc Sugar Land/Houston, Texas, USA	Oncology	Phase 2	VIEW
333.	U.S. Stem Cell, Inc. Sunrise, Florida, United States	Cardiovascular Immunology	Clinical Development	VIEW
334.	UC San Diego Health La Jolla, USA	Oncology Cardiovascular Neuroscience+1	Commercial	VIEW
335.	Ultragenyx Pharmaceutical Inc. Novato, USA	Rare Diseases	Commercial	VIEW
336.	University of British Columbia Vancouver, Canada	Oncology Infectious Disease Rare Diseases+1	Discovery	VIEW
337.	University of California, Berkeley Berkeley, USA	Oncology Immunology Neuroscience+1	Discovery	VIEW
338.	University of Cincinnati Cincinnati, USA	Oncology Neuroscience Hematology+2	Commercial	VIEW
339.	University of Colorado Boulder Boulder, USA	Oncology Rare Diseases Immunology+1	Discovery	VIEW
340.	University of Essex Colchester, United Kingdom	Oncology Neuroscience Immunology+1	Discovery	VIEW
341.	University of Wisconsin–Madison Madison, USA	Oncology Neuroscience Rare Diseases+3	Commercial	VIEW
342.	Vasa Therapeutics Encinitas, USA	Cardiovascular Metabolic	Phase 1	VIEW
343.	Vaxcyte San Carlos, California, USA	Infectious Disease Immunology	Clinical (Phase 2 and Phase 3)	VIEW
344.	Vertex Pharmaceuticals Boston, USA		Commercial	VIEW
345.	Visterra Waltham, USA	Immunology Infectious Disease Oncology	Phase 3	VIEW
346.	Vitane Pharmaceuticals Dubai, United Arab Emirates	Cardiovascular Neuroscience Gastroenterology+1	Commercial	VIEW
347.	Wisdomi Clarkdale, Arizona, USA	Oncology Immunology	Discovery	VIEW
348.	X4 Pharmaceuticals Boston, USA	Immunology Hematology Rare Diseases+1	Commercial	VIEW
349.	Xilio Therapeutics Waltham, Massachusetts	Oncology Immunology	Phase 2	VIEW
350.	Yeditepe University Istanbul, Turkey	Oncology Neuroscience	Phase 3	VIEW
351.	Zai Lab Shanghai, China and Cambridge, MA, USA	Oncology Immunology Neuroscience+1	Commercial	VIEW
352.	Zenagem Philadelphia, Pennsylvania	Oncology Neuroscience Infectious Disease	Discovery	VIEW
353.	arGenX (argenx) Amsterdam, Netherlands	Immunology	Phase 1 through Commercial	VIEW